Study of TQB3702 plus immunochemotherapy for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with either: slow-growing B-cell lymphoma that came back after treatment, or diffuse large B-cell lymphoma.
- You have at least one tumor that can be measured on scans.
- You are willing to use effective birth control during the study and for 6 months after.
- You have not had other cancers in the last 3 years (except some skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called TQB2825, given as a shot under the skin, for people with certain types of lymphoma that have not responded to previous CD20-targeted treatments. The goal is to see if the drug is safe and effective, and it might help control the cancer.
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.
This study tests a new injection (TQB2825) against standard immunotherapy for people with follicular lymphoma that has come back or hasn't responded to at least two previous treatments. The goal is to see if it can help control the cancer and improve outcomes.
This trial tests a new drug called TQB2825 combined with chemotherapy for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least one prior treatment. It aims to see if this combination can help when other treatments haven't worked and stem cell transplant is not an option.
This study tests a new pill (TQB3909) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to earlier treatments. It compares TQB3909 with the doctor's choice of standard treatment to see which works better and is safer.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.